Medscape5d
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...
The American Journal of Managed Care6d
FDA Approves Osimertinib in Stage III NSCLC
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable ...
Targeted Oncology5h
September 2024 FDA Roundup: Key Decisions Drive Oncology Forward
On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...
Business Wire6d
TAGRISSO ® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...
The American Journal of Managed Care2d
Amivantamab Presents an Exciting Treatment Opportunity in NSCLC
In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...
Yahoo Finance6d
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
September 26, 2024--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth ...
pulmonologyadvisor2d
Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC
FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...
ascopubs.org3d
Real-world outcomes among patients with advanced EGFRm NSCLC previously treated with osimertinib and platinum-based chemotherapy.
Real-world molecular testing patterns in primary advanced or recurrent endometrial cancer (pA/rEC) in the US. Health-related quality of life of Canadian patients with human epidermal growth factor ...
Morningstar6d
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Based on LAURA Phase III trial results which showed TAGRISSO extended median progression-free survival by more than three years AstraZeneca’s TAGRISSO®(osimertinib) has been approved in the ...
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
Tagrisso (osimertinib)​ for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) ...
Stockhouse6d
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
AstraZeneca’s TAGRISSO®(osimertinib)​ has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...